Viewing Study NCT02384369



Ignite Creation Date: 2024-05-06 @ 3:50 AM
Last Modification Date: 2024-10-26 @ 11:39 AM
Study NCT ID: NCT02384369
Status: WITHDRAWN
Last Update Posted: 2016-04-18
First Post: 2015-03-04

Brief Title: Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder
Sponsor: Synchroneuron Inc
Organization: Synchroneuron Inc

Study Overview

Official Title: Phase 2a Randomized Double-Blind Placebo-Controlled Trial Evaluating Efficacy Safety and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin
Status: WITHDRAWN
Status Verified Date: 2016-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Insufficient
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PTSD
Brief Summary: This is a randomized double-blind placebo-controlled study of SNC-102 in adult subjects with cPTSD added to pre-existing treatment that includes prazosin with or without other psychotropic drugs

Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder cPTSD as measured by the Clinician Administered PTSD Scale CAPS-5 compared with the response to placebo
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None